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Resistance to pentavalent antimonial (Sbv) agents such as sodium stibogluconate (SSG) is creating a major
problem in the treatment of visceral leishmaniasis. In the present study the in vivo susceptibilities of Leish-
mania donovani strains, typed as SSG resistant (strain 200011) or SSG sensitive (strain 200016) on the basis
of their responses to a single SSG dose of 300 mg of Sbv/kg of body weight, to other antileishmanial drugs were
determined. In addition, the role of glutathione in SSG resistance was investigated by determining the
influence on SSG treatment of concomitant treatment with a nonionic surfactant vesicle formulation of
buthionine sulfoximine (BSO), a specific inhibitor of the enzyme -glutamylcysteine synthetase which is
involved in glutathione biosynthesis, and SSG, on the efficacy of SSG treatment. L. donovani strains that were
SSG resistant (strain 200011) and SSG sensitive (strain 200016) were equally susceptible to in vivo treatment
with miltefosine, paromomycin and amphotericin B (Fungizone and AmBisome) formulations. Combined
treatment with SSG and vesicular BSO significantly increased the in vivo efficacy of SSG against both the
200011 and the 200016 L. donovani strains. However, joint treatment that included high SSG doses was
unexpectedly associated with toxicity. Measurement of glutathione levels in the spleens and livers of treated
mice showed that the ability of the combined therapy to inhibit glutathione levels was also dependent on the
SSG dose used and that the combined treatment exhibited organ-dependent effects. The SSG resistance
exhibited by the L. donovani strains was not associated with cross-resistance to other classes of compounds and
could be reversed by treatment with an inhibitor of glutathione biosynthesis, indicating that clinical resistance
to antimonial drugs should not affect the antileishmanial efficacies of alternative drugs. In addition, it should
be possible to identify a treatment regimen that could reverse antimony resistance.
Resistance to the main therapeutic drugs, pentavalent anti-
monial (Sbv) compounds such as sodium stibogluconate (SSG),
is creating a clinical dilemma in the treatment of visceral leish-
maniasis (1), with primary resistance now occurring in 30 to
65% of cases in some parts of India (S. Sundar, T. Jha, C.
Thakur, M. Mishra, and R. Buffels, Abstr. 40th Intersci. Conf.
Antimicrob. Agents Chemother., abstr. 177a, p. 23, 2000).
Studies with in vitro models have demonstrated that drug re-
sistance can be related to a reduction in drug influx or an
increase in drug efflux, qualitative or quantitative changes in
the drug target (8, 19), or a combination of these factors.
Molecular studies have identified a number of genes which
may be important in controlling drug resistance in Leishmania,
in particular, those which code for ATP-binding cassette
(ABC) proteins. For example, the ABC transporter PgpA has
been shown to be involved in resistance to arsenite and anti-
monial drugs since its gene is frequently amplified in selected
drug-resistant parasites (19). Sequencing studies suggest that
PgpA is a member of the multidrug resistance protein family,
which consists of ABC transporters whose substrates include
organic anions and drugs conjugated to glutathione, glucur-
onate, or sulfate. This has led to considerable interest in the
role of antioxidant thiol compounds in Leishmania infectivity
and drug resistance. The tripeptide glutathione (-glutamyl-
cysteinylglycine) is ubiquitous in aerobic organisms, but
trypanosomatids such as Leishmania and Trypanosoma also con-
tain trypanothione, formed by conjugation of glutathione with
spermidine (9). There is evidence that upregulation of genes
involved in glutathione and trypanothione biosynthesis may
correlate with increased resistance to metals (14, 15), and it is
thought that efflux of arsenite and antimony involves their
conjugation to thiols (18, 27). In addition, in vitro studies have
shown that buthionine sulfoximine (BSO), a specific inhibitor
of -glutamylcysteine synthetase, an enzyme involved in gluta-
thione and trypanothione biosynthesis, can reverse resistance to
trivalent antimony in Leishmania (13). The thiol antioxidants
may also be important in direct protection against reactive
oxygen species generated by activated macrophages (7).
We have recently characterized different strains of L. dono-
vani isolated from patients in India in 2000 as Sbv susceptible
or resistant on the basis of their response to single-dose treat-
ment with SSG at a dose of 300 mg of Sbv/kg of body weight
(3). These strains have been maintained without drug pressure
since isolation; therefore, the mechanism responsible for de-
creased susceptibility to SSG seems to be a stable genetic
change in the parasite. In this study the susceptibilities of our
SSG-resistant and -sensitive strains to other antileishmanial
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drugs were determined to ascertain whether the changes in
sensitivity to SSG treatment were drug specific or conferred
cross-resistance to other antileishmanial agents. Cross-resis-
tance to unrelated drugs with different molecular targets would
indicate that a common mechanism, e.g., a nonspecific drug
efflux pump, was responsible for the resistance observed. It is
possible to determine the importance of particular cellular
targets in drug susceptibility by using specific inhibitors or
inducers in the presence of the drug. Therefore, in this study
the importance of thiols in resistance to SSG was determined
by comparing the effects of treatment of mice with a vesicular
formulation of BSO in the presence and absence of SSG. A
nonionic surfactant vesicle (NIV) formulation of BSO was
used, since previous studies (21) have shown that this approach
increases the efficacies of a variety of antileishmanial drugs by
directing more of the drug dose to infected tissues.
MATERIALS AND METHODS
Materials. SSG was provided by Glaxo Wellcome Ltd. (Ware, United King-
dom). Sbv (31.7% [wt/wt]) was provided by Glaxo Wellcome Ltd.. Fungizone is
the proprietary brand of an amphotericin B (AMB)-sodium deoxycholate micel-
lar complex, while AmBisome is the proprietary brand of liposomal AMB. Both
were purchased from Munro Wholesalers, East Kilbride, United Kingdom. The
nonionic surfactant tetraethylene glycol mono-n-hexadecylether was purchased
from Chesham Chemicals Ltd., Harrow, United Kingdom. Paromomycin sulfate,
hexadecylphosphocholine (miltefosine), and BSO were obtained from Sigma-
Aldrich (Poole, United Kingdom). Two batches of BSO were used in the studies:
one was bought 1.5 years before use (batch 1), and one was purchased 1
month before use (batch 2). All other reagents were of analytical grade.
Animals and parasites. Age-matched BALB/c mice (weight, 20 to 25 g; male
or female mice inbred in-house) were used in this study. Commercially obtained
Golden Syrian hamsters (Mesocricetus auratus; Harlan Olac, Bicester, Oxon,
United Kingdom) were used for maintenance of the L. donovani strains. L.
donovani strains 200011 and 20016, which were clinically derived from patients in
India and collected under the regulations of the Bihar University Ethical Com-
mittee (3), were used in this study. The mice were infected by intravenous
injection (tail vein, no anesthetic) with 1  107 to 2  107 L. donovani amasti-
gotes (2). The day of parasite administration to the mice was designated day 0 of
the experiment. Animal experiments were carried out in accordance with United
Kingdom Home Office regulations and under ethical clearance from the Uni-
versity of Strathclyde’s Ethical Committee.
Vesicle formulations. A total of 300 mol of vesicle constituents, consisting of
a 3:3:1 molar ratio of mono-n-hexadecylether tetraethylene glycol, cholesterol,
and dicetyl phosphate, was melted by heating at 130°C for 5 min. The molten
mixture was cooled to 70°C and hydrated with 5 ml of preheated (70°C) phos-
phate-buffered saline (PBS) to form empty NIV or aqueous BSO to form BSO-
NIV. The vesicular formulations were homogenized at 8,000  100 rpm for 15
min at 70°C with a Silverson mixer (model L4R SU; Silverson Machines,
Chesham, United Kingdom) fitted with a 5/8-in tubular work head. The vesicle
suspensions were stored at room temperature until use.
In vivo efficacies of drug formulations. Groups of infected mice (n 4 or 5 per
treatment in each experiment) received the relevant treatment either orally or
intravenously. Mice treated orally were given PBS (controls) or miltefosine
(15 or 25 mg/kg) on days 7 to 11 as a single daily dose. This dose was chosen
on the basis of in vivo studies carried out by Murray and Delph-Etienne (24).
Mice treated intravenously were dosed on day 7 with one of the following:
PBS (controls), paromomycin (20 mg/kg), SSG solution (300 mg of Sbv/kg),
AMB deoxycholate (Fungizone; 0.375 mg of AMB/kg), or liposomal AMB
(AmBisome; 8 mg of AMB/kg). A dose of 20 mg of paromomycin/kg was chosen,
since previous studies have shown that this dose causes 50% suppression of liver
L. donovani parasite burdens (29). AmBisome and Fungizone were prepared in
accordance with the manufacturer’s instructions and were diluted prior to use
with 5% dextrose to give a final AMB concentration of 1 mg/ml. Animals were
killed at 7 days posttreatment; and parasite burdens in the spleens, livers, and
bone marrow were determined microscopically by blindly counting the number
of parasites per 1,000 host nuclei from randomly chosen slides. Organ weights
were used to calculate the Leishman donovan units (LDU) for spleen and liver
parasite burdens (2). In order to determine the importance of glutathione in SSG
susceptibility, the animals were treated intravenously on day 7 postinfection with
PBS (controls), free SSG (70.4 to 300 mg of Sbv/kg), free BSO, or BSO-NIV
mixed 1:1 with free SSG or water. The doses used in each experiment are
indicated in the Results section. The experiments were performed at least twice
to confirm the results, and the parasite burdens were determined on day 7
posttreatment.
Extraction of glutathione-thiol from tissue samples for analysis. Spleen and
liver samples collected at the time of killing were frozen in liquid nitrogen and
stored at 	70°C until extraction for glutathione analysis (within 2 weeks). Tissue
samples (approximately 0.1 g) were homogenized in 5 volumes of ice-cold
HEPES buffer (50 mM HEPES [pH 8.0], 5 mM EDTA) and then centrifuged at
10,000  g for 5 min. The supernatant was processed differently for spectropho-
tometric and high-pressure liquid chromatography analyses.
Analysis of thiols by high-pressure liquid chromatography. A 100-l aliquot
of the tissue extract supernatant was mixed with an equal volume of 2 mM
monobromobimane in ethanol and heated at 70°C for 5 min. A total of 300 l of
25% trichloroacetic acid was added, and the sample was centrifuged at 10,000 
g for 3 min. Ten microliters of the supernatant was injected onto an Ace Hichrom
C18 column, and a gradient of 0.25% (vol/vol) glacial acetic acid in water to
0.25% (vol/vol) glacial acetic acid in methanol was added at a flow rate of 0.5
ml/min over 20 min. Elution of bimane-derivatized compounds was monitored by
fluorescence detection with excitation at 398 nm and emission at 480 nm. Glu-
tathione was identified and quantitated by comparison with glutathione stan-
dards (50 M to 1 mM).
Spectrophotometric analysis of total glutathione. A 100-l aliquot of the
tissue extract supernatant was mixed with an equal volume of 10% trichloroacetic
acid and frozen-thawed once before centrifugation at 10,000  g for 3 min. The
total glutathione concentration ([GSH] and [GSSG]) was determined on the
basis of a modification of the DTNB-GSSG recycling method described by
Griffiths (12). Liver samples were diluted 10-fold and spleen samples were
diluted 2-fold prior to assay. The assay was carried out in 125 mM sodium
phosphate buffer (pH 7.4) containing 8 mM EDTA, with 100 l of 6 mM DTNB,
100 l of 1.9 mM NADPH, and 25 l of sample or glutathione standard (final
volume, 1 ml). The reaction was started by the addition of 5 l of glutathione
reductase (340 U/ml) and was monitored by determination of the increase in the
absorbance at 412 nm. The rate of the reaction was proportional to the combined
concentration of glutathione and GSSG, as determined with glutathione stan-
dards (20 to 100 M).
Presentation and statistical analysis of data. Parasite suppression (mean 
standard error of the mean [SEM] percent suppression) was determined for a
particular site by comparing each experimental parasite burden with the relevant
mean burden for the control by using the LDU per organ for the spleen and liver
and the number of parasites per 1,000 host cell nuclei for the bone marrow.
Parasite burdens were analyzed by a Students’ unpaired t test on the log10-
transformed parasite burden data.
RESULTS
Miltefosine. Oral dosing with miltefosine at 15 mg/kg by use
of a multidose treatment regimen caused a significant reduc-
tion in liver parasite burdens in mice infected with strain
200016 (mean  SEM percent suppression, 65%  10%; P 
0.01) and a significant reduction in both splenic (47%  10%;
P  0.05) and liver (86%  7; P  0.01) parasite burdens in
mice infected with strain 200011 (Table 1, experiment 1). An
increase in the drug dose to 25 mg/kg resulted in a similar
significant reduction in parasite burdens in all three sites sur-
veyed compared to the control values (mean  SEM percent
suppression of strain 200016, 98.8%  0.2% for the spleen,
99.5%  0.3% for the liver, and 48%  18% for the bone
marrow; mean  SEM percent suppression of strain 200011,
98.8%  0.5% for the spleen, 99.6%  0.2% for the liver, and
97.8%  11.4% for the bone marrow [P  0.0005]; Table 1,
experiment 2). Treatment with free SSG caused a significant (P
 0.0005) reduction (99.5%  0.3%) in liver parasite burdens
in mice infected with strain 200016 (Sbv sensitive) compared to
those in the controls. SSG treatment also caused a significant
(P  0.05) reduction (67%  12%) in splenic parasite burdens
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in one experiment (Table 1, experiment 2), but this was not
confirmed in a repeat experiment (Table 1, experiment 1). In
contrast, similar treatment of mice infected with strain 200011
(Sbv resistant) failed to have any significant effect on parasite
numbers in any of the three sites (Table 1).
Paromomycin. A single intravenous treatment with paromo-
mycin at 20 mg/kg significantly reduced the liver parasite bur-
dens in mice infected with either L. donovani strain (35% 
10% [P  0.05] for strain 200016; 53%  9% [P  0.01] for
strain 200011) compared to those in the relevant controls.
However, this dose failed to have any significant effect on
splenic or bone marrow parasite burdens compared to those in
the controls (Table 1, experiment 1).
AMB formulations. Treatment with AMB deoxycholate
(0.375 mg of AMB/kg) resulted in significant reductions in
splenic (65%  4%; P  0.01) and liver (97%  1%; P 
0.0005) parasite burdens in mice infected with L. donovani
strain 200016 but had no significant effect on bone marrow
parasite burdens compared to the burdens in the controls.
Similar treatment of mice infected with L. donovani strain
200011 caused a significant reduction in parasite burdens in all
three sites surveyed compared to the burdens in the controls
(spleen, 59% 19% [P 0.05]; liver, 96% 1% [P 0.0005];
bone marrow, 70% 7% [P 0.005]) (Table 1, experiment 1).
Treatment with liposomal AMB at 8 mg of AMB/kg had a
similar suppressive effect on the splenic, liver, and bone mar-
row parasite burdens of mice infected with L. donovani strain
200011 or 200016 (mean SEM percent suppression for strain
200016, 99.5% 0.5% for the spleen, 100% 0% for the liver,
and 97.5% 1.5% for the bone marrow; mean SEM percent
suppression for strain 200011, 94.8%  2.5% for the spleen,
99.3%  0.4% for the liver, and 99%  0.6% for the bone
marrow; Table 1, experiment 2).
BSO-NIV therapy. Treatment with BSO-NIV (BSO dose, 34
mg/kg) had a strain-dependent effect which was apparent only
when newly purchased BSO was used to prepare the formula-
tion. Thus, treatment with BSO-NIV prepared with “old”
(BSO batch 1) or “new” BSO (BSO batch 2) had no significant
effect on the parasite burdens of mice infected with L. dono-
vani strain 200011 and had no adverse effect on animal health
(Table 2). Treatment of mice infected with strain 200016 with
BSO-NIV formulated with either batch of BSO also had no
adverse effect on animal health and no significant effect on
bone marrow parasite burdens (Table 2). However, treatment
with BSO-NIV prepared with batch 1 of BSO caused a signif-
icant (P  0.05) increase in splenic parasite burdens in one
experiment (Table 2, BSO batch 1), but this result was not
obtained in another experiment with the same batch of BSO or
two subsequent experiments with BSO-NIV prepared with
fresh BSO (Table 2, batch 2). Treatment with BSO-NIV had
no significant effect on liver parasite burdens compared to the
burdens in the controls in two experiments with BSO-NIV
TABLE 1. Effects of drug treatment on burdens of different L. donovani strainsa
Expt no., strain, and
treatment (dose)
Mean  SEM % parasite burden (mean  SEM % suppression)
Spleen Liver Bone marrow
Expt 1
200016
Control 36  13 2,197 256 329 125
SSG 40  14 (21  13) 47  15b (98  1) 293  75 (25  9)
Miltefosine, oral (15 mg/kg) 27 6 (27  15) 778  228c (65  10) 258  27 (25  11)
Paromomycin (20 mg/kg) 51  2 (0  0) 1,420  216d (35  10) 394  103 (12  12)
AMB deoxycholate (0.375 mg/kg) 13 2c (65  4) 74  16b (97  1) 243  33 (26  10)
200011
Control 31  7 2,250  316 223 16
SSG 32  7 (20  14) 2,338  475 (14  9) 247  24 (3  3)
Miltefosine, oral (15 mg/kg) 17  3 (47  10d) 310  162c (86  7) 184  40 (44  12)
Paromomycin (20 mg/kg) 37  7 (8  8) 1,060  208c (53  9) 307  86 (25  16)
AMB deoxycholate (0.375 mg/kg) 13 6d (59  19) 99  25b (96  1) 99  24c (70  7)
Expt 2
200016
Control 50  8 837  91 156 25
SSG 17  6d (67  12) 5  3b (99.5  0.29) 81  29 (48  18)
Liposomal AMB (8 mg/kg) 0.25 0.25b (99.5  0.5) 0  0b (100  0) 1  1b (97.5  1.5)
Miltefosine, oral (25 mg/kg) 0.1  0.1b (99.8  0.2) 4  3b (99.5  0.31) 4  2b (97.5  1.5)
200011
Control 61  11 1,767 191 244 32
SSG 94  15 (2  2) 1,913  296 (8  50) 298  48 (4  2)
Liposomal AMB (8 mg/kg) 3  2b (94.8  2.5) 10  5b (99.3  0.4) 2  2b (99  0.6)
Miltefosine, oral (25 mg/kg) 1  0.2b (99.8  0.2) 7  4b (99.6  0.2) 6  3 (97.8  1.4)
a L. donovani-infected mice were treated orally with miltefosine (days 7 to 11, once per day) or intravenously with SSG solution (222 mg of Sbv/kg), AMB
deoxycholate, liposomal AMB, or PBS (controls). Parasite burdens were assessed on day 14 postinfection, and the mean percent suppression for each treatment was
determined.
b P  0.0005 compared to the results for the relevant control.
c P  0.01 compared to the results for the relevant control.
d P  0.05 compared to the results for the relevant control.
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prepared with batch 1 of BSO (Table 2). However, a significant
(P 0.001) reduction in liver parasite burdens was obtained in
two subsequent experiments with batch 2 of BSO (77% sup-
pression in parasite burdens compared to those in the controls;
Table 2). Unfortunately, a direct comparison by use of BSO-
NIV formulated with both batches of BSO could not be made
since the supply of batch 1 was exhausted. Total and reduced
glutathione levels in the spleen were unaffected by BSO-NIV
treatment in mice infected with either strain compared to the
levels in the controls (Table 3). BSO-NIV treatment also had
no significant effect on the levels of reduced glutathione in the
livers of mice infected with either strain compared to the levels
in the controls but caused a significant (P  0.05) reduction in
total glutathione levels in the livers of mice infected with strain
200011 but not in the livers of those infected with strain 200016
(Table 3).
SSG versus BSO-NIV and SSG therapy. As expected, treat-
ment with SSG alone (282 or 70.4 mg of Sbv/kg; Table 2) had
no significant effect on parasite burdens compared to those in
the controls in mice infected with strain 200011. However, SSG
treatment caused a significant (P  0.001) reduction (98% 
1%) in liver parasite numbers in mice infected with strain
200016 compared to the numbers in the relevant controls (Ta-
ble 2). SSG treatment (282 mg of Sbv/kg) had no significant
effect on liver glutathione levels in mice infected with either
strain compared to the levels in the controls (Table 3). How-
ever, both total (P  0.01) and reduced (P  0.01) levels of
glutathione were significantly increased by SSG treatment in
mice infected with strain 200011, whereas similar treatment of
mice infected with 200016 did not affect the glutathione levels
compared to the levels in the controls (Table 3).
Joint treatment of strain 200016-infected mice with BSO-
NIV and SSG (BSO, 34 mg/kg; SSG, 70 mg of Sbv/kg) caused
a significant reduction in parasite numbers in the spleens, liv-
ers, and bone marrow compared to the numbers in the con-
trols. This effect (P  0.001) was independent of the batch of
BSO used to prepare the BSO-NIV formulation (in four of
four separate experiments; Table 2). The reduction in liver
parasite burdens was similar to that obtained by treatment with
free SSG at 282 mg of Sbv/kg (Table 2). Similar treatment of
mice infected with strain 200011 also unexpectedly caused a
significant (P 0.001) reduction in liver parasite burdens com-
pared to those in the controls (in five of five separate experi-
ments; Table 2).
BSO-NIV and SSG treatment resulted in significantly higher
(P  0.001) splenic parasite burdens compared to those in the
controls (in five of five separate experiments; Table 2). BSO-
NIV and SSG treatment either had no significant effect on
bone marrow parasite burdens (in one of five separate exper-
iments; Table 2) or caused a significant (P  0.001) increase in
bone marrow parasite burdens (in four of five separate exper-
iments; Table 2). These effects were independent of the batch
of BSO used to prepare the BSO-NIV formulation. The SSG
dose was reduced for joint treatment since preliminary studies
TABLE 2. Effects of different treatments on parasite burdens of mice infected with L. donovani strain 200011 or 200016a
BSO batch, strain, and
treatment (dose)
Mean  SEM % parasite burden (mean  SEM % suppression)
Spleen Liver Bone marrow
Batch 1
200016
Control 18  5 855 102 145 28
SSG (282 mg of Sbv/kg) 11  2 (40  14) 15  6b (98  1) 43  15c (72  9)
BSO-NIV 38 6c (0  0) 850  64 (7  4) 287  47 (0  0)
BSO-NIV and SSG 5  1c (72  7) 11  8b (99  1.0) 11  4b (97  1)
200011
Control 10  2 567 117 101 5
SSG (282 mg of Sbv/kg) 8  2 (30  15) 476  107 (22  15) 106  9 (6  6)
BSO-NIV 14 1 (0  0) 486  1,267 (13 9) 75  25 (35  20)
BSO-NIV and SSG 58  17b (0  0) 23  9b (96  2) 87  20 (21  16)
Batch 2
200016
Control 22  4 1,681 189 305  40
SSG (70.4 mg of Sbv/kg) 30  4 (5  2) 395  60b (77  4) 367  43 (25  20)
BSO-NIV 34 7 (7  7) 571  44b (65  2) 239  36 (22  12)
BSO-NIV and SSG 0.5  0.5b (98  2) 2  2b (99.9  0.1) 82  31b (73  10)
200011
Control 58  17 2,321 282 402  137
SSG (70.4 mg of Sbv/kg) 68  15 (9  11) 3,066  496 (4  4) 426  80 (10  7)
BSO-NIV 53 18 (28  14) 2,835  207 (0  0) 459  45 (3  2)
BSO-NIV and SSG 438  37b (0  0) 154  37b (93  1) 962  173b (0  0)
a Mice (four mice per group) infected with L. donovani strain 200011 or 200016 were treated intravenously on day 7 postinfection with PBS (controls), free SSG (264
or 70.4 mg of Sbv/kg), BSO-NIV alone (BSO at 34 mg/kg), or BSO-NIV and SSG (final BSO dose of 34 mg/kg and SSG with 70.4 mg of Sbv/kg; 2 formulations were
mixed 1:1 just prior to dosing). Parasite burdens were determined on day 14 postinfection. The burdens among each group of control mice were not significantly
different. Two batches of BSO were used in the experiments: batch 1 was used 1.5 years after purchase, and batch 2 was used within 1 month of purchase.
b P  0.001 compared to the results for the relevant control.
c P  0.05 compared to the results for the relevant control.
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showed that the use of SSG at higher doses (138 mg of
Sbv/kg) resulted in a significant suppression in parasite burdens
in all three sites (at day 7 posttreatment in animals infected
with strain 200011, the burdens were suppressed 82% in the
spleen, 94% in the liver, and 94% in the bone marrow com-
pared to those in the controls). However, it also resulted in
significant acute toxicity, as demonstrated by a significant re-
duction in both body and spleen weights, and some of the
animals had to be euthanized at 2 days posttreatment.
Joint treatment with BSO-NIV and SSG with SSG at a dose
138 mg of Sbv/kg resulted in significant reductions in total
and reduced glutathione levels in the liver compared to the
levels in the controls (data not shown). Treatment with BSO-
NIV and SSG, with SSG at 70 mg of Sbv/kg, was associated
with significant increases in the levels of reduced glutathione in
the livers of infected mice (for strain 200011, P  0.05; for
strain 200016, P  0.01; Table 3), whereas total glutathione
levels were similar to the levels in the controls (Table 3). This
treatment also caused a significant increase (P  0.01) in total
glutathione levels in the spleens of mice infected with either
strain (Table 3) and a significant (P  0.01) increase in re-
duced glutathione levels in the spleens of mice infected with
strain 200011 (Table 3). Reduced glutathione levels were
higher in the spleens of mice infected with strain 200016, but
the results were not significantly different compared to those
for the controls (Table 3). In a repeat experiment, treatment
with BSO-NIV and SSG, with SSG at 70 mg of Sbv/kg, had no
significant effect on glutathione levels compared to the levels in
the controls (data not shown). However, this treatment did
cause a significant (P  0.04) increase in the level of reduced
glutathione in the livers of mice infected with strain 200011
compared to the levels in the controls.
Joint treatment with BSO-NIV and SSG was associated with
a significant increase in spleen weights in mice infected with
either strain (weights for mice infected with strain 200016, 0.18
 0.01 g for control mice and 0.32  0.01g for mice treated
with BSO-NIV and SSG; weights for mice infected with strain
200011, 0.19  0.03 g for control mice and 0.50  0.03 g for
mice treated with BSO-NIV and SSG). This increase in spleen
weight did not occur in mice treated with free SSG or BSO-
NIV alone (data not shown).
DISCUSSION
Resistance to antimonial drugs is becoming a major problem
in the treatment of visceral leishmaniasis (4; Sundar et al., 40th
ICAAC). Therefore, in areas with a high incidence of clinical
nonresponsiveness, alternatives to Sbv which are affordable to
the local medical services need to be used (23). The results of
this study indicate that decreased susceptibility to SSG is drug
specific and does not confer cross-resistance to paromomycin,
miltefosine, or AMB. This lack of cross-resistance correlates
with both experimental and clinical findings. Thus, antimony-
resistant L. infantum axenic amastigotes, induced by in vitro
drug pressure, were as susceptible to pentamidine and AMB as
wild-type clones (26). AMB treatment resulted in long-term
cure in90% of the patients who did not respond to antimony
treatment (23), and multiple doses of paromomycin (aminosi-
dine) or miltefosine gave high cure rates in an area of India
where antimony resistance is prevalent.
Studies have indicated that resistance to heavy metals such
as antimony or arsenic in Leishmania is due to the ability of the
parasite to limit drug exposure by forming metal-thiol conju-
gates with trypanothione, a parasite-specific thiol (5, 20).
These conjugates are then sequestered into an intracellular
vesicle before extrusion by specific transporters (15, 18, 19).
The results of this study indicate that glutathione biosynthesis
has a major role in SSG resistance since treatment with vesic-
ular BSO, a specific inhibitor of -glutamylcysteine synthetase,
significantly enhanced the therapeutic efficacy of SSG against
both SSG-resistant and -susceptible strains of liver parasites.
However, it is not possible to determine whether the effect
involved just glutathione, since BSO inhibits both glutathione
and trypanothione biosynthesis in trypanosomatids such as
Leishmania and Trypanosoma (9). The reason for the ability of
BSO-NIV and SSG treatment to significantly increase the
splenic parasite burdens in mice infected with strain 200011
(an SSG-resistant strain) but decrease the parasite burdens of
mice infected with strain 200016 (an SSG-susceptible strain) is
under investigation.
Combined treatment with BSO-NIV and SSG was toxic at
high SSG doses (138 mg of Sbv/kg). In vitro studies with
metal-resistant cell lines have shown that depletion of gluta-
thione after BSO treatment results in metal accumulation and
reverses drug resistance (6, 16). Therefore, the toxicity may
have been due to higher tissue antimony levels since antimony
is known to be toxic and can cause side effects such as nausea,
TABLE 3. Effects of different treatments on spleen and liver
glutathione levels in L. donovani-infected micea
Glutathione type, strain,
and treatment
Mean  SEM glutathione
level (mM)
Spleen Liver
Reduced glutathione (HPLC assay)
200016
Control 1.21 0.25 3.02  0.21
BSO-NIV 1.81 0.15 3.10  0.58
BSO-NIV and SSG 2.19 0.47 4.04  0.18b
SSG 1.78 0.25 4.36  0.19b
200011
Control 0.97 0.28 3.28  0.27
BSO-NIV 1.67 0.11 3.06  0.23
BSO-NIV and SSG 2.35 0.23b 4.23  0.27c
SSG 2.04 0.05b 3.11  0.08
Total glutathione (DTNB assay)
200016
Control 2.50 0.05 7.21  0.42
BSO-NIV 2.75 0.31 6.66  0.53
BSO-NIV and SSG 3.65 0.23b 5.94  0.70
SSG 2.43 0.22 8.44  0.29
200011
Control 2.50 0.20 7.19  0.41
BSO-NIV 2.40 0.08 5.95  0.25c
BSO-NIV and SSG 3.42 0.32b 6.29  0.60
SSG 3.10 0.01c 6.97  0.17
a Spleen and liver glutathione levels in mice treated with BSO batch 1 (Table
2).
b P  0.01 compared to the results for the relevant control.
c P  0.05 compared to the results for the relevant control.
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vomiting, diarrhea, cardiotoxicity, hepatic damage, respiratory
problems (30), and weight loss (25). Mice treated with SSG
(138 mg of Sbv/kg) and BSO-NIV in this study did exhibit a
high level of weight loss and some difficulty with their breath-
ing. These effects were eliminated by reducing the dose of SSG
used. Glutathione plays a central role in protecting against
oxidative stress, but simply inhibiting this function was not
responsible for the toxicity observed, since treatment with the
same dose of BSO-NIV alone did not result in any toxic side
effects. The toxicity associated with a single-dose BSO-NIV
and SSG treatment perhaps indicates that antimony had accu-
mulated in tissues as the SbIII form, which is much more toxic
to the host and parasite (27, 30). Incubation of the pentavalent
antimonial drug, meglumine antimoniate, with glutathione re-
sults in its reduction to the trivalent form (11), perhaps indi-
cating that bioreduction may occur before or upon drug con-
jugation to glutathione.
The anticipated reductions in glutathione levels and treat-
ment efficacy in mice treated with BSO-NIV and SSG were not
obtained. For example, treatment caused a significant reduc-
tion in splenic parasite burdens compared to those in the
controls in mice infected with SSG-susceptible strain 200016
and a significant increase in parasite burdens compared to
those in the controls in mice infected with SSG-resistant strain
200011 but had no effect or caused an increase in spleen glu-
tathione levels on day 7 posttreatment. The effect of SSG and
BSO-NIV treatment on glutathione levels depended on the
dose of SSG given, since the BSO-NIV dose remained con-
stant. Thus, the use of SSG at high doses (138 mg of Sbv/kg)
with BSO-NIV treatment resulted in significant reductions in
total and reduced glutathione levels in the liver and spleen,
whereas the use of SSG at a low dose (70.4 mg of Sbv/kg)
caused a significant increase in the levels of reduced glutathi-
one in the livers of infected mice, irrespective of the parasite’s
susceptibility to SSG, and had no effect on total glutathione
levels. Thus, the effect of modifying intracellular glutathione
levels depended on the concomitant level of oxidative stress
present (Sbv levels). Longitudinal studies are required to un-
derstand the role of glutathione in the outcome of SSG treat-
ment, since levels in tissues were determined only on day 7
posttreatment in this study.
Studies are also under way to quantify tissue antimony (Sbv
and SbIII) levels to ascertain whether these are affected by the
treatments. It may be possible to identify a more effective
combination therapy which can reverse SSG resistance without
inducing significant toxicity. This could be achieved by reduc-
ing the dose of BSO-NIV given, altering the interval between
BSO-NIV and SSG dosing, or using an NIV formulation of
DL-
-difluoromethylornithine, a specific irreversible inhibitor
of ornithine decarboxylase (10) which would inhibit trypano-
thione production but not affect glutathione synthesis. How-
ever, this approach may be unsuccessful in Leishmania, since
the drug may be poorly taken up by the parasite or may have
a low affinity for its target proteins or salvage pathways may
overcome its inhibitory effect (22).
In this study the effect of vesicular BSO treatment depended
on the strain used (an SSG-resistant or -sensitive strain) and
the age of the BSO used. Only treatment of mice infected with
SSG-sensitive strain 200016 with BSO-NIV prepared from
freshly purchased BSO had a consistent significant suppressive
effect on liver parasite burdens. This result perhaps indicates a
stability problem with BSO, although it was stored as recom-
mended by the manufacturer. BSO has already been shown to
have antileishmanial properties, since in vitro treatment of L.
donovani-infected macrophages with 5 mM BSO reduced the
percentage of cells infected and the mean number of parasites
per cell (17).
In summary, this study showed that the resistance to SSG
exhibited by clinically derived strains of L. donovani was not
associated with cross-resistance to other classes of compounds
and could be reversed by treatment with an inhibitor of gluta-
thione biosynthesis. In addition, it indicates that the high inci-
dence of clinical resistance to antimonial drugs should not
affect the clinical response to alternative drugs and that it
should be possible to identify a treatment regimen that could
reverse antimony resistance. This finding also has implications
for other diseases, e.g., cancer (28), in which glutathione has
been shown to be important in mediating drug resistance.
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